26 96
Statistical
analysis:
Crivelli,
Rink,
Shariat.
Obtaining
funding:
None.
Administrative,
technical,
or material
support:
None.
Supervision:
Rink,
Crivelli.
Other
(specify): None.
Financial disclosures:
Michael Rink
certifies
that
all
conflicts of
interest,
including
specific
financial
interests
and
relationships
and
affiliations
relevant
to
the
subject matter
or materials discussed
in
the manuscript
(eg, employment/affiliation, grants or
funding,
consultancies, honoraria,
stock ownership or options, expert
testimony,
royalties, or patents filed,
received,
or
pending),
are
the
following: Michael
Rink
is
a
speaker
for
Pfizer
Pharma.
All
the
other
authors
have
nothing
to
disclose.
Funding/Support
and
role
of
the
sponsor:
None.
Acknowledgments:
Michael Rink
is supported by a GEROK
research grant
from
the University
of Hamburg.
References
[1]
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
[2]
Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non– muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53.[3]
Kirkali Z, Chan T, ManoharanM, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4–34.[4]
Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle- invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778–92.[5]
WorldHealthOrganization. Global health risks. Geneva, Switzerland: World Health Organization; 2009.
[6]
Centers for Disease Control, Prevention. Vital signs: current ciga- rette smoking among adults aged 18 years—United States, 2005- 2010. Morb Mortal Wkly Rep 2011;60:1207–12.[7]
Giskes K, Kunst AE, Benach J, et al. Trends in smoking behaviour between 1985 and 2000 in nine European countries by education. J Epidemiol Community Health 2005;59:395–401.[8]
Simonis K, Shariat SF, Rink M. Urothelial Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol 2014;24:492–9.[9]
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89:630–9.[10]
Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014;370:60–8.[11]
Rink M, Chun FK, Chromecki TF, et al. [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies]. Urologe A 2012;51:820–8.
[12]
Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y. Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort. Urol Oncol 2015;33:65.e19–2.
[13]
Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27: 295–300.[14]
Baser S, Shannon VR, Eapen GA, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006;130:1784–90.
[15]
Land SR. Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. J Clin Oncol 2012;30: 2030–2.
[16]
Dresler CM, Leon ME, Straif K, Baan R, Secretan B. Reversal of risk upon quitting smoking. Lancet 2006;368:348–9.
[17]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
[18]
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737–45.
[19]
Alguacil J, Kogevinas M, Silverman DT, et al. Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis 2011;32:843–7.
[20]
Erdurak K, Dundar PE, Ozyurt BC, Negri E, La Vecchia C, Tay Z. Smoking, occupation, history of selected diseases and bladder cancer risk in Manisa, Turkey. Eur J Cancer Prev 2014;23:58–61.[21]
Ferreccio C, Yuan Y, Calle J, et al. Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer. Epidemiology 2013;24:898–905.
[22]
Jiang X, Castelao JE, Yuan J-M, et al. Cigarette smoking and subtypes of bladder cancer. Int J Cancer 2012;130:896–901.
[23]
Moura MA, Bergmann A, Aguiar SS, Thuler LCS. The magnitude of the association between smoking and the risk of developing cancer in Brazil: a multicenter study. BMJ Open 2014;4:e003736.[24]
Welty CJ, Wright JL, Hotaling JM, Bhatti P, Porter MP, White E. Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol 2014;32, 25.e1–5.[25]
Wu C-C, Chen M-C, Huang Y-K, et al. Environmental tobacco smoke and arsenic methylation capacity are associated with urothelial carcinoma. J Formos Med Assoc 2013;112:554–60.
[26]
Zheng Y-L, Amr S, Saleh DA, et al. Urinary bladder cancer risk factors in Egypt: a multicenter case-control study. Cancer Epidemiol Bio- markers Prev 2012;21:537–46.
[27]
Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372–7.
[28]
Zhang ZF, Sarkis AS, Cordon-Cardo C, et al. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1994;3:19–24.
[29]
Zhang ZF, Shu XM, Cordon-Cardo C, et al. Cigarette smoking and chromosome 9 alterations in bladder cancer. Cancer Epidemiol Biomarkers Prev 1997;6:321–6.[30]
Garcia-Closas M, Rothman N, Figueroa JD, et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res 2013;73:2211–20.[31]
Ajili F, Manai M, Darouiche A, Chebil M, Boubaker S. Tumor multi- plicity is an independent prognostic factor of non–muscle-invasive bladder cancer treated with bacillus Calmette-Guerin immuno- therapy. Ultrastruct Pathol 2012;36:320–4.[32]
Allard P, Fradet Y, Teˆtu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995; 1:1195–202.[33]
Chen C-H, Shun C-T, Huang K-H, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007;100:281–6.
[34]
Fleshner N, Garland JA, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco- associated superficial transitional cell carcinoma of the bladder. Cancer 1999;86:2337–45.
[35]
Gangawar R, Ahirwar D, Mandhani A, Mittal RD. Impact of nucleo- tide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol 2010;27:159–66.
[36]
Gee JR, Jarrard DF, Bruskewitz RC, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Gue´rin. BJU Int 2009;103:736–9.E U R O P E A N
U R O L O G Y
F O C U S
1
( 2 0 1 5
)
1 7 – 2 7
26